Skip to Content

Intron A Side Effects

Generic Name: interferon alfa-2b

Note: This page contains information about the side effects of interferon alfa-2b. Some of the dosage forms included on this document may not apply to the brand name Intron A.

Not all side effects for Intron A may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to interferon alfa-2b: injection kit, injection powder for solution, injection solution

In addition to its needed effects, some unwanted effects may be caused by interferon alfa-2b (the active ingredient contained in Intron A). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking interferon alfa-2b:

More common
  • Depression
  • difficult or labored breathing
  • swelling or puffiness of the face
  • tightness in the chest
  • weight loss
Less common
  • Back, leg, or stomach pains
  • bleeding, tender, or enlarged gums
  • bloody, black, or tarry stools
  • bloody nose
  • bloody or cloudy urine
  • blurred vision
  • change in personality
  • changes in behavior
  • chest pain, discomfort, or heaviness
  • chills
  • clay-colored stools
  • confusion as to time, place, or person
  • constipation
  • cough producing mucus
  • coughing or spitting up blood
  • dark urine
  • decreased urination
  • diarrhea
  • difficult or painful urination
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • drowsiness
  • fainting
  • fast, slow, pounding, irregular, or racing heartbeat or pulse
  • feeling, seeing, or hearing things that are not there
  • feeling that others are watching you or controlling your behavior
  • feeling that others can hear your thoughts
  • fever
  • hallucinations
  • headache
  • hearing loss
  • heavier menstrual periods
  • hives or rash
  • hoarseness or husky voice
  • inability to speak
  • increased thirst
  • increased urination
  • indigestion
  • irritability
  • itching, pain, redness, or swelling of the skin
  • light-colored stools
  • lightheadedness
  • loss of appetite
  • loss of consciousness
  • loss of hearing
  • lower back or side pain
  • metallic taste
  • muscle aches or cramps
  • nausea or vomiting
  • pale skin
  • passing of gas
  • pinpoint red spots on the skin
  • seizures
  • severe mood or mental changes
  • severe stomach pain with nausea and vomiting
  • slow speech
  • sneezing
  • sores, ulcers, or white spots on the lips or tongue or inside the mouth
  • stiffness of the limbs
  • stomach cramps, tenderness, or discomfort
  • stomach pain, continuing
  • stomach upset
  • sweating
  • swelling around the eyes
  • swelling of the face, fingers, hands, ankles, feet, or lower legs
  • swollen, painful, or tender lymph glands in the neck, armpit, or groin
  • thoughts of hurting or killing oneself
  • trouble sleeping
  • unusual behavior
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • weight gain
  • yellowing of the eyes or skin

Some of the side effects that can occur with interferon alfa-2b may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Acid or sour stomach
  • bleeding gums
  • blistering, crusting, irritation, itching, or reddening of the skin
  • body aches or pain
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • change in taste, or bad, unusual, or unpleasant (after) taste
  • cracked, dry, or scaly skin
  • hair loss or thinning of the hair
  • irritation in the mouth
  • joint pain
  • lack or loss of strength
  • loss of memory
  • muscle or bone pain
  • pain or tenderness around the eyes and cheekbones
  • poor concentration
  • problems with memory
  • redness and swelling of the gums
  • stuffy or runny nose
  • swollen joints
Less common
  • Abnormal ejaculation
  • absent, missed, or irregular menstrual periods
  • bleeding, burning, inflammation, itching, or pain at the injection site
  • bone deformity
  • burning, itching, and pain in the hairy areas, pus at the root of the hair
  • burning, numbness, pain, or tingling in all fingers except smallest finger
  • cold and clammy skin
  • decrease in height
  • decreased interest in sexual intercourse
  • degenerative disease of the joint
  • difficulty with moving or walking
  • discoloration of the skin
  • inability to have or keep an erection
  • increased clear or white vaginal discharge
  • increased sensitivity of the skin to sunlight
  • itching or pain of the genital area
  • leg cramps
  • longer menstrual periods
  • loss in sexual ability, desire, drive, or performance
  • multiple swollen and inflamed skin lesions
  • pain in the ankles or knees
  • pain in the ribs
  • pain, inflammation, or swelling in the calves, shoulders, or hands
  • painful, red lumps under the skin, mostly on the legs
  • pelvic pain
  • rash with flat lesions or small raised lesions on the skin
  • red or irritated eyes
  • redness or swelling in the arms or legs
  • redness, tenderness, itching, burning, or peeling of the skin
  • severe sunburn
  • shivering
  • skin rash, encrusted, scaly, and oozing small lumps under the skin
  • small lumps under the skin
  • soreness of the muscles
  • stopping of menstrual bleeding
  • swelling or redness in the joints
  • tanning or blue-gray discoloration of the skin
  • tearing of the eyes
  • underactive reflexes
  • unexpected menstrual bleeding

For Healthcare Professionals

Applies to interferon alfa-2b: injectable kit, injectable powder for injection, injectable solution


Clinical trials were conducted for various indications using a wide range of doses (from 6 million international units/m2/week in hairy cell leukemia up to 100 million international units/m2/week in melanoma). Most side effects reported during clinical trials were mild to moderate in severity and manageable. Some side effects were transient and most diminished with continued therapy. Influenza-like symptoms (mainly fever, headache, rigors/chills, myalgia, malaise, and fatigue) were reported most often; these side effects were reversible within 72 hours after interrupting or stopping therapy. Side effects were dose-related. In general, more severe toxicities were observed at higher doses; hematologic, hepatic, cardiovascular, and neurologic toxicities were more common with higher doses.

The manufacturer product information for ribavirin should be consulted, if applicable.[Ref]


Very common (10% or more): Fatigue (up to 96%), pyrexia (up to 94%), influenza-like symptoms (up to 79%), asthenia (up to 63%), chills (up to 54%), rigors (up to 42%), chest pain (up to 28%), irritability (up to 22%), unspecified pain (up to 18%), moniliasis (up to 17%), malaise (up to 14%), decreased weight (up to 13%), viral infection
Common (1% to 10%): Facial edema, nonspecific infection, peripheral edema, herpes simplex resistance, thirst, flushing, breast pain
Uncommon (0.1% to 1%): Bacterial infection
Rare (0.01% to 0.1%): Sepsis, resistance mechanism disorders (e.g., altered resistance to infection [rarely life-threatening or fatal]), weakness
Very rare (less than 0.01%): Cachexia, earache, hot flashes/flushes, fungal infection, malignant hyperpyrexia
Frequency not reported: Hernia, edema, hypothermia, nonspecific inflammation, mastitis, increased weight, substernal chest pain, hyperthermia, abscess, Haemophilus, infection, parasitic infection, otitis media, Trichomonas
Postmarketing reports: Asthenic conditions (including asthenia, malaise, fatigue)[Ref]


Very common (10% or more): Decreased granulocyte count (up to 92%), neutropenia (up to 92%), decreased WBC count (up to 68%), decreased hemoglobin (up to 32%), anemia (up to 27%), decreased platelet count (up to 15%), leukopenia
Common (1% to 10%): Thrombocytopenia, bleeding, lymphadenopathy, lymphopenia
Very rare (less than 0.01%): Aplastic anemia, pure red cell aplasia, hemolytic anemia, coagulation disorder, splenomegaly
Frequency not reported: Hypochromic anemia, granulocytopenia, lymphadenitis, lymphocytosis, thrombocytopenia purpura
Postmarketing reports: Pancytopenia (concurrent anemia, leukopenia, thrombocytopenia), idiopathic thrombocytopenia purpura, thrombotic thrombocytopenic purpura[Ref]

Aplastic anemia and pure red cell aplasia have also been reported during postmarketing experience.[Ref]


Myositis has also been reported during postmarketing experience.[Ref]

Very common (10% or more): Myalgia (up to 75%), musculoskeletal pain (up to 21%), arthralgia (up to 19%), back pain (up to 19%)
Common (1% to 10%): Arthritis
Rare (0.01% to 0.1%): Rhabdomyolysis (sometimes serious), myositis, leg cramps
Very rare (less than 0.01%): Arthrosis, bone pain, muscle weakness, myopathy
Frequency not reported: Arthritis aggravated, bone disorder, carpal tunnel syndrome, muscle atrophy, tendinitis, rheumatoid arthritis (new or aggravated), spondylitis, twitching[Ref]


Very common (10% or more): Anorexia (up to 69%), increased alkaline phosphatase (up to 13%)
Common (1% to 10%): Hypocalcemia, dehydration, hyperuricemia
Uncommon (0.1% to 1%): Increased LDH
Rare (0.01% to 0.1%): Diabetes mellitus, hyperglycemia, increased appetite
Very rare (less than 0.01%): Acidosis, aggravation of diabetes mellitus, hypercalcemia, hypertriglyceridemia
Frequency not reported: Alcohol intolerance[Ref]


Very common (10% or more): Nausea (up to 66%), diarrhea (up to 45%), vomiting (up to 32%), dry mouth (up to 28%), abdominal pain (up to 23%), right upper quadrant pain (up to 15%), constipation (up to 14%), gingivitis (up to 14%), stomatitis, dyspepsia
Common (1% to 10%): Loose stools, gastrointestinal (GI) disorder, ulcerative stomatitis, glossitis
Rare (0.01% to 0.1%): Gingival bleeding
Very rare (less than 0.01%): Abdominal distension, colitis, dysphagia, eructation, esophagitis, flatulence, gastric ulcer, GI hemorrhage, GI mucosal discoloration, gum hyperplasia, ileus, increased saliva, ischemic colitis, melena, oral leukoplakia, pancreatitis, rectal bleeding after stool, rectal hemorrhage, tenesmus, tongue disorder, ulcerative colitis
Frequency not reported: Abdominal ascites, gallstones, gastritis, gastroenteritis, halitosis, hemorrhoids, intestinal disorder, mouth ulceration, mucositis, oral hemorrhage, tooth disorder, periodontal disorder (not otherwise specified), dental disorder (not otherwise specified)[Ref]

Pancreatitis has also been reported during postmarketing experience.[Ref]


Worsening liver disease, including jaundice, hepatic encephalopathy, hepatic failure, and death have been reported after use of this drug in patients with decompensated liver disease, autoimmune hepatitis, or history of autoimmune disease, and in immunosuppressed transplant recipients.[Ref]

Very common (10% or more): Elevated AST (up to 63%), elevated ALT (up to 15%)
Common (1% to 10%): Hepatomegaly
Rare (0.01% to 0.1%): Hepatotoxicity (including fatality)
Very rare (less than 0.01%): Abnormal hepatic function tests, bilirubinemia, hepatic encephalopathy, hepatic failure, hepatosplenomegaly, jaundice
Frequency not reported: Biliary pain, hepatitis, increased transaminases (AST/ALT), worsening liver disease[Ref]

Nervous system

Impaired consciousness included cases of encephalopathy.

Frontal subcortical dysfunction and choreic movements of the limbs appeared in a 68-year-old woman almost 2 years after the start of interferon alfa-2b (the active ingredient contained in Intron A) (3 x 10[6] units/day) for chronic myeloid leukemia. She had no history of psychiatric disorders and no hereditary neurodegenerative disease with long-term recombinant interferon therapy. Symptoms of personality changes, short memory loss, and choreic movements progressively worsened over a 4 month period until she became bedridden. One month after this drug was discontinued, patient's cognitive performance had improved and choreic movements had disappeared. Clinical examination of her cognitive performances at six and 12 months later were normal.

Peripheral neuropathy and hearing loss have also been reported during postmarketing experience.[Ref]

Very common (10% or more): Headache (up to 62%), somnolence (up to 33%), dizziness (up to 24%), altered taste/taste perversion (up to 24%), paresthesia (up to 21%), impaired concentration (up to 14%), amnesia (up to 14%)
Common (1% to 10%): Hypoesthesia, vertigo, tremor, migraine, tinnitus
Uncommon (0.1% to 1%): Peripheral neuropathy
Rare (0.01% to 0.1%): Impaired consciousness, neuropathy, polyneuropathy, seizure
Very rare (less than 0.01%): Abnormal coordination, abnormal gait, aphasia, ataxia, central nervous system dysfunction, cerebrovascular hemorrhage, cerebrovascular ischemia, coma, convulsions, deafness, dementia, dystonia, encephalopathy, extrapyramidal disorder, hearing disorder, hearing loss, hyperacusis, hyperesthesia, hyperkinesia, hypertonia, oculomotor nerve paralysis, paralysis, paresis, speech disorder, stupor, syncope, taste loss
Frequency not reported: Bell's palsy, hearing impairment, hypokinesia, hyporeflexia, labyrinthine disorder, loss of consciousness, mononeuropathies, neuralgia, neuritis, parosmia, stroke, frontal subcortical dementia, choreic movements mimicking Huntington's disease[Ref]


Psychosis (including hallucinations) has also been reported during postmarketing experience.[Ref]

Very common (10% or more): Depression (up to 40%), confusion (up to 12%), insomnia (up to 12%), anxiety, emotional lability, nervousness, agitation
Common (1% to 10%): Decreased libido, sleep disorder
Uncommon (0.1% to 1%): Suicidal ideation, suicide attempt, suicide
Rare (0.01% to 0.1%): Aggressive behavior (sometimes directed against others), psychosis (including hallucinations)
Very rare (less than 0.01%): Abnormal thinking, apathy, depression aggravated, feeling of ebriety, neurosis, paroniria, personality disorder
Frequency not reported: Abnormal dreaming, delirium, manic depression, mania, psychosis, mental status change, bipolar disorders
Postmarketing reports: Homicidal ideation[Ref]


Case reports of aseptic necrosis of the skin and ulceration have been described in patients with Kaposi's sarcoma associated with HIV infection treated with this drug.

Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and urticaria have also been reported during postmarketing experience.[Ref]

Very common (10% or more): Alopecia (up to 38%), rash (up to 25%), increased sweating (up to 21%), pruritus (up to 11%), dry skin
Common (1% to 10%): Dermatitis, purpura, herpes simplex, psoriasis (new or aggravated), maculopapular rash, erythematous rash, eczema, erythema, skin disorder
Very rare (less than 0.01%): Abnormal hair texture, acne, chloasma, dermatitis lichenoides, epidermal necrolysis, erythema multiforme, furunculosis, increased hair growth, melanosis, nail disorders, nonherpetic cold sores, photosensitivity, skin depigmentation, skin discoloration, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vitiligo
Frequency not reported: Cellulitis, cold and clammy skin, erythema nodosum, folliculitis, herpes zoster, lipoma, pallor, sebaceous cyst, skin nodule, urticaria, hair discoloration, trichomegaly, radiation recall dermatitis (manifested as erythematous macular rash in region of irradiation), aseptic necrosis of the skin and ulceration, lipoatrophy, cutaneous vasculitides[Ref]


Pulmonary arterial hypertension (PAH) has been reported with alpha interferons, particularly in patients with risk factors for PAH (e.g., portal hypertension, HIV infection, cirrhosis). Such events occurred at various time points normally several months after starting interferon alfa therapy.

Severe asthma developed in 2 patients as soon as 8 weeks after the start of this drug in patients diagnosed with chronic hepatitis C and mild asthma.

Pulmonary fibrosis has also been reported during postmarketing experience.[Ref]

Very common (10% or more): Dyspnea (up to 34%), coughing (up to 31%), pharyngitis (up to 31%), sinusitis (up to 21%), nonproductive cough (up to 14%)
Common (1% to 10%): Nasal congestion, bronchitis, rhinitis, epistaxis, respiratory disorder, rhinorrhea
Rare (0.01% to 0.1%): Pneumonia, pulmonary infiltrates, pneumonitis
Very rare (less than 0.01%): Bronchospasm, hypoxia, laryngitis, pleural pain, pulmonary edema, pulmonary embolism, pulmonary fibrosis, sneezing, stridor, wheezing
Frequency not reported: Asthma, dysphonia, hemoptysis, hypoventilation, pleural effusion, orthopnea, pneumothorax, pulmonary arterial hypertension, rales, respiratory insufficiency, tonsillitis, tracheitis, upper respiratory tract infection, severe asthma
Postmarketing reports: Pulmonary hypertension[Ref]


Injection site necrosis has also been reported during postmarketing experience.[Ref]

Very common (10% or more): Injection site inflammation (up to 20%), injection site reaction
Common (1% to 10%): Injection site pain
Rare (0.01% to 0.1%): Injection site disorders
Very rare (less than 0.01%): Injection site necrosis
Frequency not reported: Burning, injection site bleeding, itching[Ref]


Very common (10% or more): Increased serum urea nitrogen levels (up to 12%)
Common (1% to 10%): Increased serum creatinine
Rare (0.01% to 0.1%): Renal failure, renal insufficiency
Very rare (less than 0.01%): Nephrotic syndrome, nephrosis

Nephrotic syndrome, renal failure, and renal insufficiency have also been reported during postmarketing experience.


Very common (10% or more): Amenorrhea (up to 12%)
Common (1% to 10%): Polyuria, urinary tract infection, micturition frequency, dysmenorrhea, menorrhagia, menstrual disorder, vaginal disorder
Very rare (less than 0.01%): Cystitis, hematuria, impotence, leukorrhea, micturition disorder, nocturia, oliguria, urinary incontinence, uterine bleeding, vaginal hemorrhage
Frequency not reported: Albumin/protein in urine, dysuria, genital pruritus, incontinence, menstrual irregularity, pelvic pain, penis disorder, scrotal/penile edema, sexual dysfunction, vaginal dryness[Ref]


Serous retinal detachment has also been reported during postmarketing experience.[Ref]

Very common (10% or more): Blurred vision
Common (1% to 10%): Conjunctivitis, abnormal vision, eye pain, lacrimal gland disorder
Rare (0.01% to 0.1%): Retinal hemorrhage, retinopathies (including macular edema), retinal artery or vein obstruction, optic neuritis, papilledema, loss of visual acuity or visual field, cotton wool spots
Very rare (less than 0.01%): Diplopia, dry eyes, night blindness, periorbital edema, photophobia, retinal disorder, serous retinal detachment, stye
Frequency not reported: Lacrimation, nystagmus
Postmarketing reports: Vogt-Koyanagi-Harada syndrome[Ref]


Cardiovascular side effects (especially arrhythmia) appeared to be associated with preexisting cardiovascular disease and prior use of cardiotoxic agents.[Ref]

Common (1% to 10%): Hypertension, palpitations, tachycardia
Uncommon (0.1% to 1%): Hypotension
Rare (0.01% to 0.1%): Cardiomyopathy, peripheral ischemia
Very rare (less than 0.01%): Angina pectoris, arrhythmia, atrial fibrillation, bradycardia, cardiac failure, cardiac ischemia, cyanosis, extrasystoles, myocardial infarction, postural hypotension, thrombophlebitis
Frequency not reported: Arteritis, cardiomegaly, coronary artery disorder, cyanosis of the hand, heart valve disorder, hematoma, phlebitis, poor peripheral circulation, polyarteritis nodosa, Raynaud's disease, superficial phlebitis, thrombosis, varicose vein, vasculitis, congestive heart failure, pericardial effusion[Ref]


Common (1% to 10%): Hypothyroidism, hyperthyroidism
Very rare (less than 0.01%): Gynecomastia, virilism
Frequency not reported: Goiter, increased thyroid-stimulating hormone levels
Postmarketing reports: Hypopituitarism[Ref]


Very rare (less than 0.01%): Sarcoidosis, exacerbation of sarcoidosis, increased gamma globulins, transplant rejection
Frequency not reported: Autoimmune disorders, immune-mediated disorders
Postmarketing reports: Systemic lupus erythematosus[Ref]

A broad range of autoimmune and immune-mediated disorders have been reported with alpha interferons including thyroid disorders, systemic lupus erythematosus, rheumatoid arthritis (new or aggravated), idiopathic and thrombotic thrombocytopenic purpura, vasculitis, neuropathies (including mononeuropathies), and Vogt-Koyanagi-Harada syndrome.

Sarcoidosis and exacerbation of sarcoidosis have also been reported during postmarketing experience.[Ref]


Frequency not reported: Allergic reaction
Postmarketing reports: Acute hypersensitivity reactions (including anaphylaxis, angioedema, urticaria, bronchoconstriction)


1. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

4. Malik UR, Makower DF, Wadler S "Interferon-mediated fatigue." Cancer 92(6 Suppl) (2001): 1664-8

5. Valles L, Gonzalez M, Polo I, Enguita AB, Vanaclocha F, Ortiz-Romero PL "Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma." Arch Dermatol 145 (2009): 98-9

6. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. "Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha." Gastroenterology 123 (2002): 141-51

7. Kirkwood JM, Bender C, Agarwala S, et al. "Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy." J Clin Oncol 20 (2002): 3703-18

8. Moulignier A, Allo S, Zittoun R, Gout O "Recombinant interferon-alpha-induced chorea and frontal subcortical dementia." Neurology 58 (2002): 328-9

9. Bonaccorso S, Marino V, Puzella A, et al. "Increased Depressive Ratings in Patients With Hepatitis C Receiving Interferon-alpha-Based Immunotherapy Are Related to Interferon-alpha-Induced Changes in the Serotonergic System." J Clin Psychopharmacol 22 (2002): 86-90

10. Udina M, Castellvi P, Moreno-Espana J, et al. "Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis." J Clin Psychiatry 73 (2012): 1128-38

11. Sheremata WA, Taylor JR, Elgart GW "More on interferon-induced cutaneous necrosis." N Engl J Med 333 (1995): 1223-4

12. Trautinger F, Knobler RM "More on interferon-induced cutaneous necrosis." N Engl J Med 333 (1995): 1222-3

13. Thomas R, Stea B "Radiation recall dermatitis from high-dose interferon alfa-2b." J Clin Oncol 20 (2002): 355-7

14. Hernandez-Nunez A, Fernandez-Herrera J, Buceta LR, Garcia-Diez A "Trichomegaly following treatment with interferon alpha-2b." Lancet 359 (2002): 1107

15. Sanders S, Busam K, Tahan SR, Johnson RA, Sachs D "Granulomatous and suppurative dermatitis at interferon alfa injection sites: Report of 2 cases." J Am Acad Dermatol 46 (2002): 611-616

16. Wollina U, Graefe T, Fuller J "Granulomatous slack skin or granulomatous mycosis fungoides -- a case report.Complete response to percutaneous radiation and interferon alpha." J Cancer Res Clin Oncol 128 (2002): 50-4

17. Bini EJ, Weinshel EH "Severe exacerbation of asthma: A new side effect of interferon-alpha in patients with asthma and chronic hepatitis C." Mayo Clin Proc 74 (1999): 367-70

18. Hejny C, Sternberg P, Lawson DH, Greiner K, Aaberg TM "Retinopathy associated with high-dose interferon alfa-2b therapy." Am J Ophthalmol 131 (2001): 782-7

19. Hamnvik OP, Larsen PR, Marqusee E "Thyroid dysfunction from antineoplastic agents." J Natl Cancer Inst 103 (2011): 1572-87

20. Eland IA, Rasch MC, Sturkenboom MJCM, Bekkering FC, Brouwer JT, Delwaide J, Belaiche J, Houbiers G, Stricker BHC "Acute pancreatitis attributed to the use of interferon alfa-2b." Gastroenterology 119 (2000): 230-3

21. Aleksza M, Lukacs A, Antal-Szalmas P, Hunyadi J, Szegedi A "Increased frequency of intracellular interleukin (IL)-13 and IL-10, but not IL-4, expressing CD4+ and CD8+ peripheral T cells of patients with atopic dermatitis." Br J Dermatol 147 (2002): 1135-41

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.